Episode Mania & Hipomania

01Pathophysiology

The core pathophysiology of a manic episode revolves around excessive dopaminergic and noradrenergic activity in the limbic system and prefrontal cortex. This neurochemical excess produces the hallmark triad of mania: elevated mood, increased energy, and psychomotor agitation. Understanding this mechanism is essential because every symptom a patient displays can be traced directly back to this overactivation.

Dopamine excess in the mesolimbic pathway drives euphoria, grandiosity, and reward-seeking behavior. This is why manic patients engage in reckless spending, risky sexual behavior, and impulsive decisions. When dopamine activity becomes severely dysregulated, it can produce psychotic features such as delusions of grandeur or persecution, which are hallmarks of the most severe subtype. This same dopaminergic mechanism explains why antipsychotics (dopamine antagonists) are effective in acute mania.

Norepinephrine excess accounts for the hyperarousal state: decreased need for sleep, hyperactivity, pressured speech, and distractibility. The patient is physiologically "overdriven." This is why patients with mania can go days with minimal sleep and still feel energized, a finding that is nearly pathognomonic on exam vignettes.

A critical concept tested repeatedly is that the Manic Episode category in the PPDGJ-III applies only to a single (first) episode. If the patient has any prior history of an affective episode (depressive, manic, or hypomanic), the diagnosis shifts to Bipolar Affective Disorder. This is a frequent trap in exam questions: a patient who presents with mania but has a documented prior depressive episode should not be labeled as having a manic episode alone.

Serotonin dysregulation also plays a modulatory role, particularly in the irritable variant of mania. Some patients do not present with euphoria but instead with marked irritability and aggressiveness, which can mimic other conditions and lead to diagnostic confusion.

02Classification and Clinical Manifestation

The PPDGJ-III divides manic episodes into three primary subtypes, each with distinct diagnostic thresholds and clinical features. The table below captures the essential distinctions:

• Hypomania is the "exam-friendly" subtype because it hinges on two negative criteria that are commonly tested: (1) the patient must not have hallucinations or delusions, and (2) the functional impairment must not be severe or comprehensive. The moment either of these conditions is met, the diagnosis upgrades to mania. Also note that hypomania must exceed what would be expected in cyclothymia, meaning the mood elevation is clearly abnormal and persistent, not merely a personality trait.

• Mania without psychotic symptoms introduces a firm 1-week minimum duration and the requirement for near-total functional disruption. The PPDGJ-III emphasizes that the patient's work and social activities are almost entirely disrupted. Key clinical features include decreased need for sleep (not insomnia, but genuinely not needing sleep), pressured speech, and grandiose ideas. These three symptoms are the most frequently tested.

• Mania with psychotic symptoms adds the dimension of psychosis. Critically, the PPDGJ-III states that the delusions and hallucinations must be "mood-congruent" (sesuai dengan keadaan afek). This means grandiosity escalates into delusions of grandeur, and irritability/suspiciousness escalates into delusions of persecution. If the psychotic features are mood-incongruent (bizarre, unrelated to mood), the examiner is pointing you toward schizoaffective disorder instead.

Two additional residual categories exist in the PPDGJ-III: Other Manic Episodes (for presentations that do not neatly fit the above subtypes) and Manic Episode, Unspecified (when information is insufficient for further classification). These rarely appear in exam questions but are worth knowing as valid diagnostic options.

03Diagnostic Workup

The diagnosis of a manic episode is fundamentally clinical. There is no laboratory test or imaging study that confirms mania. The examiner is testing whether you can recognize the pattern from the vignette and apply the PPDGJ-III criteria correctly. The best initial diagnostic step is always a thorough psychiatric interview using structured criteria.

That said, the workup serves a critical second purpose: excluding organic and substance-induced causes. This is where students often lose marks. When a patient presents with a first episode of elevated mood, increased energy, and grandiosity, the differential must include hyperthyroidism and stimulant intoxication before the diagnosis of a primary manic episode can be made. The PPDGJ-III itself lists hyperthyroidism and anorexia nervosa as differential diagnoses for hypomania, reinforcing the importance of a thyroid panel.

Thyroid function tests are the single most important laboratory study in the workup. Hyperthyroidism produces anxiety, agitation, weight loss, insomnia, and hyperactivity, which overlap substantially with hypomania. A suppressed TSH with elevated free T4 redirects the diagnosis entirely.

Urine toxicology is the second priority. Cocaine and amphetamine intoxication can produce a clinical picture indistinguishable from acute mania: euphoria, grandiosity, decreased sleep, pressured speech, and even paranoid delusions. A positive toxicology screen does not necessarily exclude a primary manic episode (substances can trigger mania in predisposed individuals), but it changes the management approach.

Baseline labs (renal function, hepatic function, CBC, electrolytes) are ordered not for diagnostic purposes but because they are required before initiating pharmacotherapy. Lithium is nephrotoxic, and valproate is hepatotoxic. If the vignette describes a patient about to start lithium and asks for the "next best step," the answer is baseline renal function and thyroid studies.

Neuroimaging is not routine. It is reserved for atypical presentations: first episode after age 40, presence of focal neurological signs, confusion or delirium out of proportion to mood symptoms, or failure to respond to standard treatment.

04Management and Treatment

Step 1: Ensure safety and acute stabilization. A manic patient, particularly one with psychotic features, may be agitated, aggressive, or a danger to themselves or others. The first priority is behavioral stabilization. Lorazepam 1 to 2 mg intramuscularly is the go-to agent for acute agitation because it acts rapidly, is safe in combination with most agents, and does not carry the metabolic burden of antipsychotics. This can be repeated every 4 to 6 hours, with a typical maximum of 6 to 8 mg in 24 hours.

Step 2: Initiate a mood stabilizer. Lithium remains the gold-standard mood stabilizer for acute mania and long-term prophylaxis. It is started at 600 to 900 mg per day in two to three divided doses and titrated upward based on serum levels drawn at steady state (5 to 7 days after initiation or dose change). The therapeutic range for acute mania is 0.8 to 1.2 mEq/L. For maintenance therapy, the target is lower: 0.6 to 0.8 mEq/L. Lithium has a narrow therapeutic index, so monitoring is essential. Toxicity presents with tremor, ataxia, dysarthria, and at severe levels, seizures and renal failure.

Before starting lithium, the following must be obtained: serum creatinine, BUN, urinalysis, thyroid function tests, ECG (in patients over 40), and a pregnancy test in women of reproductive age. Lithium is teratogenic (associated with Ebstein anomaly) and is contraindicated in the first trimester of pregnancy.

Valproate (divalproex sodium) is the preferred alternative when lithium is contraindicated, poorly tolerated, or when the patient has rapid cycling (four or more episodes per year). It is started at 750 mg/day in divided doses and titrated to a serum level of 50 to 125 mcg/mL. Key side effects include hepatotoxicity, thrombocytopenia, pancreatitis, and teratogenicity (neural tube defects). Baseline liver function tests and CBC are required. Valproate is also contraindicated in pregnancy.

Carbamazepine is a second-line mood stabilizer, used when both lithium and valproate are contraindicated or ineffective. It is started at 400 mg/day and titrated to 800 to 1600 mg/day. The therapeutic level is 4 to 12 mcg/mL. Notable side effects include aplastic anemia, agranulocytosis, SIADH, and Stevens-Johnson syndrome. It is a potent CYP450 inducer, leading to numerous drug interactions.

Step 3: Add an atypical antipsychotic if psychotic features are present. When a patient meets criteria for mania with psychotic symptoms (delusions of grandeur, delusions of persecution, mood-congruent hallucinations), a mood stabilizer alone is not sufficient. The standard of care is combination therapy: mood stabilizer plus atypical antipsychotic. Preferred agents include:

• Olanzapine 10 to 20 mg/day (effective but carries significant metabolic risk: weight gain, dyslipidemia, hyperglycemia)

• Risperidone 2 to 6 mg/day (effective with lower metabolic burden but higher risk of extrapyramidal symptoms and hyperprolactinemia)

• Quetiapine 400 to 800 mg/day (favorable side-effect profile; also useful if insomnia is prominent)

Even in mania without psychotic features, atypical antipsychotics can be used as monotherapy or in combination when rapid symptom control is needed.

Step 4: Long-term maintenance. After acute stabilization, the patient must remain on maintenance pharmacotherapy to prevent recurrence. Lithium has the strongest evidence base for long-term prophylaxis and also carries a unique benefit: reduction of suicide risk in mood disorders. Maintenance valproate is used when lithium is not tolerated. The duration of maintenance therapy is typically indefinite after a manic episode, as recurrence rates are high.

Critical contraindication to remember: Never prescribe an antidepressant as monotherapy to a patient with a history of mania. Antidepressant monotherapy can precipitate a manic switch or induce rapid cycling. If an antidepressant is needed (for a subsequent depressive episode), it must always be paired with a mood stabilizer.

05Differential Diagnosis and Distractors

06Traps and High-Yield Pearls

The most common way students lose marks on manic episode questions is by failing to classify the episode correctly within the PPDGJ-III hierarchy. The critical rule is deceptively simple: the manic episode category is only for a single, first-time episode. If the vignette buries a single line about a "prior depressive episode two years ago" or "a similar episode in the past," the diagnosis must shift to bipolar affective disorder. Test-writers love embedding this detail in the middle of the stem, and students who focus only on the current presentation will miss it.

The second trap involves confusing hypomania with mania. The distinguishing factors are duration, severity, and the presence or absence of psychotic features. Many vignettes describe a patient who is "more energetic than usual, talking more, sleeping less, and taking on new projects" but who continues to function at work. This is hypomania, not mania. The moment the vignette states that the patient's occupational or social functioning is "severely disrupted" or that symptoms have lasted at least one week, the diagnosis upgrades to mania.

The third trap targets the mood-congruence rule in mania with psychotic symptoms. If the vignette describes a manic patient hearing voices telling them they are a prophet (grandiose, mood-congruent), the diagnosis is mania with psychotic features. But if the same patient hears voices commenting on their actions or experiences thought insertion (mood-incongruent, Schneiderian first-rank symptoms), the examiner is redirecting you toward schizophrenia or schizoaffective disorder.

A fourth, frequently tested pearl: never give antidepressant monotherapy to a patient with current or past mania. This is one of the most reliable "wrong answer choices" on the exam. If a vignette describes a patient in a depressive phase and the answer choices include "start fluoxetine alone," that answer is always incorrect if there is any history of mania.

Finally, remember the baseline workup before pharmacotherapy. A vignette that asks for the "next step" before starting lithium is looking for renal function tests, thyroid function tests, and ECG. A vignette asking for the next step before starting valproate is looking for liver function tests and CBC. These are predictable, high-yield questions.

The core competency being tested in manic episode questions is threefold: (1) accurate subtype classification based on duration, severity, and the presence or absence of psychosis; (2) recognition that a prior affective episode changes the diagnosis; and (3) correct sequencing of management, including pre-treatment workup and the contraindication of antidepressant monotherapy.